CURI stock forecast, quote, news & analysis

CURI in upward trend: price rose above 50-day moving average on September 10, 2026

CURI moved above its 50-day moving average on September 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on CURI as a result. In 65 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for CURI just turned positive on September 15, 2026. Looking at past instances where CURI's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.

Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where CURI advanced for three days, in 170 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 117 of 141 cases where CURI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for CURI moved out of overbought territory on September 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 16 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CURI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

CURI broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CURI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.437) is normal, around the industry mean (3.894). CURI's P/E Ratio (1606.560) is considerably higher than the industry average of (153.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.298). CURI has a moderately high Dividend Yield (0.106) as compared to the industry average of (0.035). P/S Ratio (2.156) is also within normal values, averaging (8.232).

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CURI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

CURI paid dividends on September 18, 2026